11/3/2021

speaker
Simona
Conference Specialist

one third quarter investor conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press the starting one on your telephone keypad. To withdraw your question, please press the starting two. Please note, this event is being recorded. At this time, I would like to turn the call over to Vincent Peroni, Director, Corporate Communication at Synthetix Biologics. Vincent?

speaker
Vincent Peroni
Director, Corporate Communication at Synthetix Biologics

Thank you, Simona, and good afternoon, everyone. Welcome to Synthetix Biologics 2021 Third Quarter Investor Conference Call. Today, I'm joined by Stephen Shawcross, our Chief Executive and Chief Financial Officer, Dr. Michael Calico, Senior Vice President, Research and Development, and Dr. Vince Wager, Head of Product and Corporate Development. Synthetic Biologics issued a press release this afternoon, which provided operational highlights and reported our financial results for the quarter ending September 30th, 2021. The release can be found in the investor relations section of our website, syntheticbiologics.com. During our call, we'll provide an operational update on our GI and microbiome focus clinical programs, and we'll summarize our financial results. We'll take questions after prepared remarks. In addition to the phone line, This call is being streamed live via webcast, which will be archived on our website for about 90 days. During this call, we'll be making forward-looking statements regarding Synthetic Biologics' current expectations and projections about future events. Generally, the forward-looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes, and estimates, and similar expressions. These statements are based upon current beliefs, expectations, and assumptions, and are subject to a number of risks and uncertainties, including those set forth in synthetic biologics filings with the SEC, many of which are difficult to predict. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. The information on this call is provided only as of the date of this call, and synthetic biologics undertakes no obligation to update any forward-looking statements contained on this conference call on accounts of new information, future events or otherwise, except as required by law. With that, I'll now turn the call over to Steve. Steve?

speaker
Stephen Shawcross
Chief Executive and Chief Financial Officer

Thank you, Vincent. Good afternoon, everyone, and thank you for joining our 2021 Third Quarter Investor Conference Call. We continue to make significant progress on our clinical programs, and I could not be more excited by the outlook for our business. Our balance sheet remains stronger than ever with $72 million cash on hand at the end of the quarter, providing us with substantial runway to support our operations into 2023. Within this time, we expect to execute on a number of key milestones related to our current therapeutic pipeline that we believe will drive significant value for shareholders. In addition, our strong balance sheet has enabled us to actively evaluate a variety of strategic options, which could include potentially acquiring or licensing new therapies that could complement and further enhance our current pipeline. We look forward to providing updates on our progress. In terms of some of the near-term milestones, first, We anticipate reporting data from the first antibiotic cohort of the SIN4 phase 1A2B clinical trial during the first quarter of 2022. Second, we look forward to reporting the data readout from our ongoing phase 1 multiple ascending dose clinical trial of SIN20 during the second quarter of 2022. I'll discuss more about each of these in a moment, but as you can see, we're in the midst of a very exciting period for our company. Turning now to the quarter. First, on CIN20, we previously announced that patient enrollment, dosing and evaluation was completed in a phase one open label single ascending dose or SAD clinical trial of CIN20, a proprietary formulation of intestinal alkaline phosphatase or IAP, intended to treat local and systemic diseases stemming from inflammation of the GI tract and disruption of the gut barrier, including radiation neuropathy and celiac disease. Analysis of preliminary data from the SADS study demonstrated SYN20 maintained a favorable safety profile and was well-tolerated at all dose levels. During the third quarter, we initiated a phase one placebo-controlled multiple ascending dose clinical study of CIN20. I'm pleased to report that the first cohort of eight study participants will complete final dosing and PK sampling this week with dosing of the second cohort of eight study participants expected to begin shortly thereafter pending a safety review. Importantly, Both Phase I studies are designed to support the development of SIN20 and multiple potential clinical indications. Turning to SIN4, Washington University continues to screen and enroll patients for our Phase I B2A clinical trial in L-Genea comedopoietic cell transplant, or HCT, recipients for the prevention of acute graft-versus-host disease. A data readout for the first of three antibiotic cohorts is anticipated during the first quarter of 2022. As I've stated before, we believe both CIN4 and CIN20 may address very sizable and underserved markets and have the potential to be foundational long-term value drivers for our company and our shareholders. With that backdrop, I'd like to provide a more detailed update on our clinical development activities, beginning with our SYN4 or Rabaxamase program. SYN4 is our first-in-class therapeutic intervention designed to protect the gut microbiome from antibiotic-mediated dysbiosis. We believe protection of the gut microbiome may play a pivotal role in improving health outcomes for patients administered long courses of intravenous beta-lactam antibiotics as part of their treatment plan for bone marrow and solid organ transplantations. We continue to advance this program in the form of a Phase 1b2a clinical trial in allogeneic HCT recipients with our partner, the Washington University School of Medicine in St. Louis. This study is designed to evaluate the safety, tolerability, and pharmacokinetics of SYN4 in this fragile patient population. Earlier this year, We announced that enrollment and patient dosing had commenced in the first of three sequential antibiotic cohorts that will each be administered a different IV beta-lactam antibiotic to treat fever following conditional therapy. In total, eight participants in each cohort will receive SYN4 and four will receive placebo. At this time, patient screening and enrollment of the first cohort remains ongoing. However, we are experiencing short delays in patient recruitment as a result of demand from competing trials and a lower number of transplant recipients whose underlying disease warrants high intensity conditioning. Despite these delays, which are outside of our control, The trial is progressing and we look forward to reporting the data readout from the first antibiotic cohort during the first quarter of 2022. Assuming these results are in line with our expectations and we observe that SYN4 is not systemically absorbed in this first cohort, we'll consider applying for orphan drug designation and begin preparations for our Phase III program while we complete the remainder of this clinical trial. I'd like to provide an update on our CIN20 intestinal alkaline phosphatase or IAP program. We continue to view CIN20 as a versatile therapeutic that has the potential to treat a number of clinical indications stemming from inflation of the GI tract and disruption of the gut barrier, including enteropathy, secondary radiation therapy used to treat certain cancers, and celiac disease, both of which have a significant unmet medical need. Importantly, we've overcome the manufacturing hurdles which have previously hindered the clinical and commercial development of IAP to treat these diseases. CIN20 is our proprietary recombinant form of bovine IAP produced in show cells and formulated for oral delivery. IAP is an endogenous enzyme expressed in the upper small intestine that plays an important role in maintaining gut health through at least three important mechanisms. First, it diminishes GI inflammation by detoxifying inflammatory molecules. Second, it acts directly on the intestinal wall to tighten the gut barrier to diminish leaky gut. And third, it functions to support a healthy gut microbiome. In addition, we believe CIN20 has the potential to diminish low-grade systemic inflammation, which is believed to exacerbate metabolic syndrome and accelerate the progression of diseases associated with aging. We previously outlined in detail our clinical development strategy for CIN20, which includes the completion of safety studies before progressing into phase two proof of concept clinical trials in a target indication. Earlier this year, we announced the completion of a Phase I open-label single ascending dose clinical trial, which evaluated safety, tolerability, and biodistribution of SYN20 in 24 healthy adult volunteers. Analysis of preliminary data from this study demonstrated that SYN20 was well-tolerated at all dose levels, and no adverse events were attributed to study drug. Importantly, no serious adverse events were reported, and as anticipated, CIN20 was not detected in the systemic circulation. During the third quarter, we initiated a phase one placebo-controlled multiple ascending dose clinical study of CIN20. This clinical study is intended to evaluate the safety, tolerability, and biodistribution of CIN20 upon repeated dosing in up to 32 healthy adult volunteers. The study is divided into four sequential cohorts of eight participants with four doses of CIN20 given orally twice daily for 14 days. As I mentioned earlier, I'm pleased to report that the first cohort of eight study participants will complete final dosing and PK sampling this week. And dosing of the second cohort of eight study participants is expected to begin in relative short order pending a safety review. we expect top-line data readout from this clinical study during the second quarter of 2022. Assuming successful completion of the Phase I MAD study, we anticipate conducting a placebo-controlled Phase IIa clinical trial as early as the second half of next year. And one of our initial target indications enteropathy secondary to radiation therapy used to treat abdominal and pelvic cancers, or celiac disease. Looking ahead, we are also considering potential Phase II clinical trials of SYN20 to evaluate its therapeutic utility and additional indications, including non-alcoholic fatty liver disease, diseases stemming from disruption of the gut barrier, as well as metabolic and inflammatory disorders associated with aging. the latter of which are supported by our exclusive option license agreement with Massachusetts General Hospital. We are excited about this versatile program and its potential to become a platform therapeutic for our company. We believe CIN20 will play a major role in driving long-term value to our shareholders while targeting large, underserved markets, including celiac disease. With that backdrop, I'll review our financial results for the quarter ended September 30, 2021. Our balance sheet remains very strong and we are well capitalized to support our operations for the foreseeable future as we reported approximately $72.1 million of cash on hand at the end of the third quarter. Our strengthened financial position and current cash runway provides more than sufficient funding to achieve a number of major milestones, including the completion of ongoing Phase 1B2A clinical trial of SIN 4, completion of clinical trials for SIN 20 through proof of concept, and other key value drivers for the company. Before reviewing our financials for the quarter, I'd like to mention that in addition to the 10Q, we will be filing a registration statement this evening covering warrants associated with our 2018 public offering of common stock. The registration statement filed this evening will supersede an expiring registration statement and should be viewed simply as a housekeeping matter. Now turning to the third quarter financial results. General administrative expenses increased. by 9% to approximately $1.3 million for the three months ended September 30, 2021 from approximately $1.2 million for the three months ended September 30, 2020. This increase is primarily due to higher insurance cost, audit fees, and registration fees offset by lower legal costs and vacation expense. Research and development expenses increased by 116% to approximately $2 million for the three months ended September 30, 2021 from approximately $900,000 for the three months ended September 30, 2020. This increase is primarily the result of increased clinical trial expenses as we continued dosing patients in the Phase 1b2a clinical trial of SIN4 and by higher indirect program costs for the three months ended September 30, 2021, including an increase in manufacturing costs for SIN20. We anticipate research and development expense to increase as our ongoing clinical trials continue to enroll patients. To wrap up, the remainder of 2021 promises to be a very exciting time for synthetic biologics. We are very happy with our progress and remain focused on executing on our strategy. As I previously stated, I'm more confident than ever and the outlook for our business and believe we have the financial strength to execute and deliver on our clinical strategy. At the same time, we continue to actively evaluate a variety of potential opportunities that could further expand our clinical development pipeline through licensing, acquisitions, or other strategic options where we believe we can further enhance value for our shareholders. I'm proud of the progress we've made and even more excited about what lies ahead. I'd like to thank our shareholders for their ongoing support, and we look forward to keeping you updated on our progress. Now I'll turn the call back to Vincent to open the call for questions.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-